INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.
[INmune Bio, Inc.]
7992332
{7992332:nan}
apa
50
1
164523
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/